John Sakys, serving as Chief Financial Officer at Mesa Laboratories Inc. (NASDAQ: MLAB), executed a sale of 1,223 shares of the company's common stock on June 16, 2026. The transaction was processed at a price of $101.267 per share, resulting in total proceeds of approximately $123,849. This divestment comes as Mesa Laboratories shares have demonstrated notable momentum, rising 25% over the preceding six months and currently trading near $98.41. Independent analysis from InvestingPro suggests the stock may be undervalued at present levels, placing it on their list of Most Undervalued opportunities.
According to a recent Securities and Exchange Commission filing, the sale was initiated to cover tax obligations linked to the vesting of restricted stock units (RSUs) on June 15, 2026. Following this transaction, Mr. Sakys directly holds 16,538 shares of Mesa Laboratories common stock. He also indirectly holds 50 shares as a custodian for his children.
The stock sale coincides with recent operational challenges for Mesa Laboratories. The company reported fourth-quarter results that fell short of consensus estimates. Revenues were 2% below expectations, with the Biological Products Division experiencing a 32% decline in core revenue. This decrease was attributed to export-control related shipping delays and poor commercial execution. Despite these headwinds, Jefferies raised its price target for Mesa Laboratories to $130 from $115, maintaining a Buy rating on the stock.
Leadership changes are also underway at Mesa Laboratories. The company announced the upcoming departure of President and CEO Gary Owens, effective April 13, 2026. Owens will remain in a non-executive role until June 22, 2026, to aid in the transition. Additionally, Mesa Laboratories appointed Lyndsey Crennen as the new chief accounting officer, effective upon her entry into a new employment agreement. Crennen, who joined Mesa Laboratories in 2018, brings over 20 years of accounting experience.
The intersection of executive transactions, financial performance, and leadership transitions highlights the dynamic environment for Mesa Laboratories investors. While valuation metrics suggest potential upside, operational setbacks and regulatory shipping constraints present near-term uncertainties. The company's ability to navigate export-control delays and maintain commercial execution will be critical for future performance.